

DHE
A
% of Control
200
150
100
50
0
0.1
1
10
100
1000
HMC
B
% of Control
200
150
100
50
0
0.1
1
10
100
1000
Cisplatin
C
% of Control
200
150
100
50
0
0.1
1
10
100
1000
Concentration (uM)

Fig. 1



120
100
80
60
40
20
0
Percent Control
0.000001
0.0001
0.01
1
100
Concentration
Cisplatin ctrl MM200
HMC MM200
Cisplatin Control A2058
HMC A2058
HMC IGR3

Fig. 2



HMC PK (p.o.)
A
Total HMC
Free HMC
HMC (uM)
1000
100
10
1
0.1
HO
O
OH
OMe
DHE PK (p.o.)
B
Total DHE
Free DHE
Dehydroequol (uM)
1000
100
10
1
0.1
0.1
1
10
100
Time (hr)

Fig. 3



10000.00
1000.00
100.00
10.00
1.00
0.10
0.01
HMC Serum concentration (uM)
HMC (50 mg/kg HPBCD i.v.)
HMC (50 mg/kg HPBCD i.p.)
0.10
1.00
10.00
100.0
Time (hr)

Fig. 4



Tumour Volume
500.00
400.00
300.00
200.00
100.00
0.00
Volume (mm3)
0
5
10
15
20
Time (days)
vehicle
HMC
*

Fig. 5




Fig. 6



Percent change in Body
Percent Change
12
10
8
6
4
2
0
0
5
10
15
20
Time (days)
vehicle
HMC

Fig. 7



Apoptosis induction in melanoma (24 hr)
A
Percent apoptosis
60
50
40
30
20
10
0
DHE
HMC
MEL-RM
ME4405
IGR3
Mel-AT
TRAIL sensitive
TRAIL-resistant
TRAIL +ve / Caspase 8 -ve
Control
1 uM drug
2 uM drug
4 uM drug
8 uM drug
24 uM drug
Apoptosis induction in melanoma (48 hr)
B
Percent apoptosis
Series1
Series2
Series3
Series4
Series5
Series6

Fig. 8



Percentage of apoptotic cells
45
40
35
30
25
20
15
10
5
0
24 hours
48 hours
MRC-5
Mel-RM
Me4405
MRC-5
Mel-RM
Me4405
DHE
HMCT

Fig. 9

Fig. 10A







Fig. 10B









30
20
10
0
-10
-20
-30
-40
-50
-60
Percentage inhibition of TNFa compared to vehicle control
10μM
1μM
0.1μM
0.001μM
0.01μM
Concentration (uM)
Compound 6
Compound 7

Fig. 11




Fig. 12